Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Natural History of NAFLD/NASH
Mattias Ekstedt, Patrik Nasr, Stergios Kechagias
Current Hepatology Reports (2017) Vol. 16, Iss. 4, pp. 391-397
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 522
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
Jeffrey V. Lazarus, Henry E. Mark, Marcela Villota‐Rivas, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 771-780
Open Access | Times Cited: 193
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
D. Huang, Jason Behary, Amany Zekry
Internal Medicine Journal (2019) Vol. 50, Iss. 9, pp. 1038-1047
Closed Access | Times Cited: 175
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
Lingxuan An, Ulrich Wirth, Dominik Koch, et al.
Journal of Gastrointestinal Surgery (2021) Vol. 26, Iss. 3, pp. 671-683
Open Access | Times Cited: 128
Defining comprehensive models of care for NAFLD
Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 10, pp. 717-729
Closed Access | Times Cited: 107
A global research priority agenda to advance public health responses to fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 618-634
Open Access | Times Cited: 68
A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
Manca Povsic, On Yee Wong, Richard Perry, et al.
Advances in Therapy (2019) Vol. 36, Iss. 7, pp. 1574-1594
Open Access | Times Cited: 122
Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota
Wenlong Sun, Xinyu Li, Hao-Yue Dou, et al.
Cell Reports (2021) Vol. 36, Iss. 9, pp. 109641-109641
Open Access | Times Cited: 81
LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease
Jun Liu, Tao Tang, Guodong Wang, et al.
Bioscience Reports (2019) Vol. 39, Iss. 7
Open Access | Times Cited: 77
Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
Martina Colognesi, Daniela Gabbia, Sara De Martin
Biomedicines (2020) Vol. 8, Iss. 7, pp. 229-229
Open Access | Times Cited: 77
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Ajay Duseja, Shivaram Prasad Singh, Arka De, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 2, pp. 273-302
Open Access | Times Cited: 50
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Lung‐Yi Mak, Ed Gane, Christian Schwabe, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 4, pp. 684-692
Closed Access | Times Cited: 40
The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States
Zobair M. Younossi, James M. Paik, Linda Henry, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 3, pp. 454-467
Open Access | Times Cited: 39
Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice
Ting Bao, Fang He, Xiaoxia Zhang, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 68
Reproducibility and repeatability of MRI‐based body composition analysis
Magnus Borga, André Ahlgren, Thobias Romu, et al.
Magnetic Resonance in Medicine (2020) Vol. 84, Iss. 6, pp. 3146-3156
Open Access | Times Cited: 66
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
Joost P.H. Drenth, Jörn M. Schattenberg
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 12, pp. 1365-1375
Open Access | Times Cited: 62
Sub‐phenotyping Metabolic Disorders Using Body Composition: An Individualized, Nonparametric Approach Utilizing Large Data Sets
Jennifer Linge, Brandon Whitcher, Magnus Borga, et al.
Obesity (2019) Vol. 27, Iss. 7, pp. 1190-1199
Open Access | Times Cited: 57
Natural History of Simple Steatosis or Nonalcoholic Fatty Liver
Arka De, Ajay Duseja
Journal of Clinical and Experimental Hepatology (2019) Vol. 10, Iss. 3, pp. 255-262
Open Access | Times Cited: 55
Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
Clara Yieh Lin Chong, David Orr, Lindsay D. Plank, et al.
Nutrients (2020) Vol. 12, Iss. 4, pp. 937-937
Open Access | Times Cited: 52
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Richard Radun, Michael Trauner
Seminars in Liver Disease (2021) Vol. 41, Iss. 04, pp. 461-475
Open Access | Times Cited: 51
The Effectiveness of eHealth Interventions on Lifestyle Modification in Patients With Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis
Oh Young Kwon, Jin-young Choi, Yeonsoo Jang
Journal of Medical Internet Research (2022) Vol. 25, pp. e37487-e37487
Open Access | Times Cited: 28
Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa
Ramiro Manzano-Núñez, Jesús Rivera‐Esteban, Jordi Navarro, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 19
Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review
Aitor Odriozola, Álvaro Santos‐Laso, María Del Barrio, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7791-7791
Open Access | Times Cited: 19
Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review
Sofía Montemayor, Silvia García, Margalida Monserrat-Mesquida, et al.
Nutrients (2023) Vol. 15, Iss. 18, pp. 3987-3987
Open Access | Times Cited: 17
Extracellular vesicles from periodontal pathogens regulate hepatic steatosis via Toll‐like receptor 2 and plasminogen activator inhibitor‐1
Ho Kim, Younggap Lim, Ji Sun Jang, et al.
Journal of Extracellular Vesicles (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top